Search Medical Condition
Please enter condition
Please choose location
 

Dementia Clinical Trials

A listing of Dementia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (933) clinical trials

The purpose of this study is to evaluate whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants who are asymptomatic at risk for developing Alzheimer's dementia.

Phase N/A

The main purpose of this study is to evaluate the efficacy of the study drug known as LY3314814 in participants with mild Alzheimer's disease (AD) dementia.

Phase

This study is testing an oral investigational study drug in people who have been experiencing a decline in memory function, and/or who have been diagnosed with mild Alzheimer’s disease. The main objective of the study is to see whether this drug can slow the decline in memory and mental functioning ...

Phase

DAYBREAK-ALZ — the study will last 8 weeks to see if you qualify, plus 3 years of treatment, then 4 weeks of follow-up. The study drug is a tablet, to be taken once a day. The tablet will contain either a lower dose of the study drug, a higher dose ...

Phase

If you qualify, the study may involve 3 screening visits, 1 separate in-clinic stay of 5 days/4 nights and 10 outpatient visits. All study exams and procedures are provided at no cost to you. You do not need medical insurance to participate.

Phase

Are you AGITATED or frustrated? Have you had memory loss? Could it be Alzheimer's disease or dementia? For some people, dementia and Alzheimer's disease (AD) can make them feel restless or upset. The ITI-007-201 Agitation Study is looking at an investigational medication to see if it is safe and works ...

Phase N/A

NAVIGATE-AD is a 52 week (plus a 4 week follow up visit), double blind study where participants will be randomly assigned (like the flip of a coin) to receive either 1 of 2 doses of study drug (LY32022626) or a placebo (tablet containing no active ingredients, similar to a "sugar ...

Phase